Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Docetaxel + Nivolumab in Recurrent/Metastatic SCCHN
NCT05027204Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel in squamous cell carcinoma of the head and neck (HNSCC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
albumin-bound docetaxel
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05027204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027204.